Exploitations with a panel of CRC lines and PDOs bearing different mutational setting and primary colonocytes demonstrated that interestingly the AT9283 treatments impacted on MKK3 protein levels reducing both phosphorylated and total protein (Fig. 1C) in all tested CRC lines. The gene discussed is MAP2K3; the disease is colorectal carcinoma.